FARMAKOKINETIK GLIKLAZID DAN SIPROFLOKSASIN PADA PEMBERIAN BERSAMA DI TIKUS WISTAR JANTAN

• Main Author: Leo, Margaretha
• Format: Final Project
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/45398
• Institution: Institut Teknologi Bandung

Diabetes Mellitus (DM) is a disease characterized by a decrease in body’s metabolism ability, which could be caused by a decrease in insulin secretion and/or increase in cellular resistance to insulin. The prevalence of DM is increasing, which could further impair other organs, one of which is renal dysfunction. This condition could be worsened by the occurrence of urinary tract infection. The most commonly treatment used to treat urinary tract infection in nephropathy diabetic patients is ciprofloxacin. This research was aimed to evaluate the pharmacokinetic interactions of gliclazide and ciprofloxacin. Wistar male rats divided into four groups (each n = 5). Group I and II received gliclazide and ciprofloxacin respectively. Group III received both gliclazide and ciprofloxacin with gliclazide induction for 10 days, and group IV received both gliclazide and ciprofloxacin with ciprofloxacin induction for 10 days. Blood samples were collected at pre-determined sampling points, then analyzed by HPLC. Pharmacokinetic parameters for both drugs were determined. Clearance of gliclazide showed a significant increase (p<0.05) in group IV (268,18 ± 53,74 mL/h/kg) compared to group I (172,36 ± 39,39 mL/h/kg). Pharmacokinetics parameters of ciprofloxacin with concomitant administration of gliclazide, both single and multiple doses, showed a significant increase (p<0.05) in biological half life (2.70 ± 0.95 to 7.47 ± 3.10 and 9.24 ± 4.74 h), AUC0-24 (3.95 ± 0.83 to 11.75 ± 4.55 and 8.45 ± 0.66 µg.h/mL), AUC0- ?(4.13 ± 0.89 to 12.57 ± 4.92 and 10.37 ± 2.26 µg.h/mL) and a significant decrease in clearance (20717.21 ± 4591.26 to 7648.18 ± 3722.45 and 8448.23 ± 1492.35 mL/h.kg). Administration of gliclazide with multiple dose of ciprofloxacin increased the clearance of gliclazide. Ciprofloxacin when given with gliclazide, either by single or multiple doses caused a significant impacts on pharmacokinetics of ciprofloxacin.